Actimed Therapeutics is a clinical stage biopharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed was founded in 2017 by two world leading physicians in muscle wasting research.

The lead area of focus for Actimed is specifically in cachexia. Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality. Despite this, there is no globally approved drug for the treatment or prevention of cancer-related cachexia. It has been estimated that cachexia affects 50-80% of cancer patients and accounts for up to 20% of cancer deaths. Treating cancer cachexia successfully may increase both the length and quality of life for cancer patients.

The lead product of Actimed, S-pindolol (ACM-001.1), targets multiple pathways that drive cachexia and has generated promising proof of concept Phase II clinical data in cachexia patients. Actimed is currently preparing for further clinical studies in cachexia in Non-Small Cell Lung Cancer {NSCLC) and Colorectal Cancer (CRC).

Actimed also has the global rights for S-oxprenolol in amyotrophic lateral sclerosis {ALS), where loss of body mass and muscle wasting may impact survival.